Recent News

• 06.09.2025 - COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES
• 06.04.2025 - COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS
• 05.30.2025 - COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
• 05.28.2025 - COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
• 05.14.2025 - COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS
• 04.15.2025 - CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies
• 03.26.2025 - 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Recent Filings

• 06.09.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.09.2025 - EX-99.1 EX-99.1
• 06.04.2025 - D Notice of Exempt Offering of Securities
• 06.04.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.04.2025 - EX-99.1 EX-99.1
• 06.02.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 06.02.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.30.2025 - EX-99.1 EX-99.1
• 05.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]